Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom

References

• KDIGO. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(Supl. 1):1–150.
   Web of Science ®Google Scholar
• Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252. doi: 10.1016/s0140-6736(16)32064-5.
   PubMed Web of Science ®Google Scholar
• Lv JC, Zhang LX. Prevalence and disease burden of chronic kidney disease. Adv Exp Med Biol. 2019;1165:3–15. doi: 10.1007/978-981-13-8871-2_1.
   PubMed Web of Science ®Google Scholar
• GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709–733. doi: 10.1016/s0140-6736(20)30045-3.
   PubMed Web of Science ®Google Scholar
• Kidney Research UK. Kidney disease: a UK public health emergency – the health economics of kidney disease to 2033 [Internet]. 2023 [cited 2023 Nov 29]. Available from: https://www.kidneyresearchuk.org/about-us/influencing-change/health-economics-report/
   Google Scholar
• Silva Junior GBD, Oliveira JGR, Oliveira MRB, et al. Global costs attributed to chronic kidney disease: a systematic review. Rev Assoc Med Bras. 2018;64(12):1108–1116. doi: 10.1590/1806-9282.64.12.1108.
   PubMed Web of Science ®Google Scholar
• Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127. doi: 10.1056/NEJMoa2204233.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Prescribing information (Great Britain) JARDIANCE® (empagliflozin) [Internet]. 2023 [cited 2023 Nov 29]. Available from: https://pro.boehringer-ingelheim.com/uk/bipdf/gb-metabolism-jardiance
   Google Scholar
• European Medicines Agency. Jardiance [Internet]. [cited 2023 Nov 29]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance
   Google Scholar
• Uster A, Ramos M, Gerlier L, et al. CKD progression model (CKD-PM): development and validation. Presented at: Kidney Week 2023; 2023 Nov 1–5; Philadelphia, PA.
   Google Scholar
• Grams ME, Surapaneni A, Appel LJ, et al. Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort study. Nephrol Dial Transplant. 2021;36(9):1685–1693. doi: 10.1093/ndt/gfaa364.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Development and validation of QDiabetes-2018 risk prediction algorithm to estimate future risk of type 2 diabetes: cohort study. BMJ. 2017;359:j5019. doi: 10.1136/bmj.j5019.
   PubMedGoogle Scholar
• Lash JP, Go AS, Appel LJ, et al. Chronic Renal Insufficiency Cohort (CRIC) study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol. 2009;4(8):1302–1311. doi: 10.2215/CJN.00070109.
   PubMed Web of Science ®Google Scholar
• Coresh J, Heerspink HJL, Sang Y, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7(2):115–127. doi: 10.1016/S2213-8587(18)30313-9.
   PubMed Web of Science ®Google Scholar
• Naimark DM, Grams ME, Matsushita K, et al. Past decline versus current eGFR and subsequent mortality risk. J Am Soc Nephrol. 2016;27(8):2456–2466. doi: 10.1681/asn.2015060688.
   PubMed Web of Science ®Google Scholar
• James MT, Grams ME, Woodward M, et al. A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury. Am J Kidney Dis. 2015;66(4):602–612. doi: 10.1053/j.ajkd.2015.02.338.
   PubMed Web of Science ®Google Scholar
• Liem YS, Bosch JL, Hunink MM. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health. 2008;11(4):733–741. doi: 10.1111/j.1524-4733.2007.00308.x.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). TA775-Dapagliflozin for treating chronic kidney disease [Internet]. 2022 [cited 2023 Nov 29]. Available from: https://www.nice.org.uk/guidance/ta775/documents/committee-papers
   Google Scholar
• National Institute for Health and Care Excellence (NICE). British National Formulary (BNF) [Internet]. 2022 [cited 2023 Nov 29]. Available from: https://bnf.nice.org.uk/
   Google Scholar
• Pollock C, James G, Garcia Sanchez JJ, et al. Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort. Clin Kidney J. 2022;15(11):2124–2134. doi: 10.1093/ckj/sfac168.
   PubMed Web of Science ®Google Scholar
• Matsushita K, Jassal SK, Sang Y, et al. Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets. eClinicalMedicine. 2020;27:100552. doi: 10.1016/j.eclinm.2020.100552.
   PubMedGoogle Scholar
• Tangri N, Grams ME, Levey AS, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA. 2016;315(2):164–174. doi: 10.1001/jama.2015.18202.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual [Internet]. 2022 [updated 2023 Aug 1; cited 2023 Nov 29]. Available from: https://www.nice.org.uk/process/pmg36/chapter/economic-evaluation#measuring-and-valuing-health-effects-in-cost-utility-analyses
   Google Scholar
• Anon. Net Health Benefit [online]. York (UK): York Health Economics Consortium; 2016. Available from: http://www.yhec.co.uk/glossary/net-health-benefit/
   Google Scholar
• Major RW, Shepherd D, Medcalf JF, et al. The Kidney Failure Risk Equation for prediction of end stage renal disease in UK primary care: an external validation and clinical impact projection cohort study. PLoS Med. 2019;16(11):e1002955. doi: 10.1371/journal.pmed.1002955.
   PubMed Web of Science ®Google Scholar
• (NICE) NIfHaCE. Chronic kidney disease: assessment and management (NG203). 2021. Available from: https://www.nice.org.uk/guidance/ng203/resources/chronic-kidney-disease-assessment-andmanagement-pdf-66143713055173
   Google Scholar
• AstraZeneca. Forxiga 10 mg film-coated tablets – summary of product characteristics UK [Internet]. 2022 [cited 2023 Nov 29]. Available from: https://www.medicines.org.uk/emc/product/7607/smpc#gref
   Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816.
   PubMed Web of Science ®Google Scholar
• McEwan P, Darlington O, Miller R, et al. Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17(12):1730–1741. doi: 10.2215/cjn.03790322.
   PubMed Web of Science ®Google Scholar
• Ghetti G, Pradelli L, Papageorgiou G, et al. CELESTIA: cost-effectiveness analysis of empagliflozin versus sitagliptin in patients with type 2 diabetes in Greece. Clinicoecon Outcomes Res. 2023;15:97–109. doi: 10.2147/ceor.S400522.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). TA336-Empagliflozin in combination therapy for treating type 2 diabetes [Internet]. 2015 [cited 2023 Nov 29]. Available from: https://www.nice.org.uk/guidance/ta336/history
   Google Scholar
• Ramos M, Cummings MH, Ustyugova A, et al. Long-term cost-effectiveness analyses of empagliflozin versus oral semaglutide, in addition to metformin, for the treatment of type 2 diabetes in the UK. Diabetes Ther. 2020;11(9):2041–2055. doi: 10.1007/s13300-020-00883-1.
   PubMed Web of Science ®Google Scholar
• Reifsnider OS, Kansal AR, Franke J, et al. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. ESC Heart Fail. 2020;7(6):3910–3918. doi: 10.1002/ehf2.12985.
   PubMed Web of Science ®Google Scholar
• Kansal A, Reifsnider OS, Proskorovsky I, et al. Cost-effectiveness analysis of empagliflozin treatment in people with type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med. 2019;36(11):1494–1502. doi: 10.1111/dme.14076.
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Zinman B, et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: insights from the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2020;22(12):2335–2347. doi: 10.1111/dom.14158.
   PubMed Web of Science ®Google Scholar
• Reifsnider OS, Kansal AR, Wanner C, et al. Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial. Am J Kidney Dis. 2022;79(6):796–806. doi: 10.1053/j.ajkd.2021.09.014.
   PubMed Web of Science ®Google Scholar